Spectral Medical Inc (TSE:EDT) Director Kevin Arnold Giese Buys 50,000 Shares

Spectral Medical Inc (TSE:EDT) Director Kevin Arnold Giese purchased 50,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of C$0.75 per share, with a total value of C$37,500.00. Following the completion of the transaction, the director now directly owns 3,426,336 shares in the company, valued at approximately C$2,569,752.

TSE EDT traded up C$0.02 on Friday, reaching C$0.75. The company had a trading volume of 42,200 shares, compared to its average volume of 94,059. The stock has a market capitalization of $155.81 million and a P/E ratio of -57.69. The company’s fifty day moving average is C$0.75 and its 200 day moving average is C$0.55. Spectral Medical Inc has a 52-week low of C$0.30 and a 52-week high of C$0.85. The company has a quick ratio of 3.64, a current ratio of 4.24 and a debt-to-equity ratio of 21.26.

Spectral Medical (TSE:EDT) last released its quarterly earnings results on Thursday, November 14th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$0.53 million during the quarter. On average, research analysts expect that Spectral Medical Inc will post -0.06 EPS for the current year.

About Spectral Medical

Spectral Medical Inc focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan.

Further Reading: Portfolio Manager

Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.